AML Therapy: Wake Up the Guardian and Cut Loose the Executioners Dario C. Altieri Cancer Cell Volume 32, Issue 6, Pages 719-720 (December 2017) DOI: 10.1016/j.ccell.2017.11.010 Copyright © 2017 Elsevier Inc. Terms and Conditions
Figure 1 Antileukemic Effect of the Combination of Venetoclax Plus RG7388 Simultaneous inhibition of Bcl-2/Bax-Bak complexes (Venetoclax) and reactivation of p53 tumor suppressor function (RG7338) results in kinase-dependent destabilization and proteasomal destruction of anti-apoptotic Bcl-2 family protein, Mcl-1, oligomerization of Bax at the outer mitochondrial membrane, and activation of apoptosis. Cancer Cell 2017 32, 719-720DOI: (10.1016/j.ccell.2017.11.010) Copyright © 2017 Elsevier Inc. Terms and Conditions